Sunpeaks Ventures Announces Acquisition of Bryce Rx Laboratories
SILVER SPRING, Md., Dec. 14, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") announces the acquisition of Bryce Rx Laboratories of Stamford, CT. Bryce Rx Laboratories, Inc, specializes in the formulation of drugs that are not commercially available, require alternate delivery systems and dosing changes. Services include customized formulations for Urology and Women's Health. Bryce also offers specialized formulations for Dermatology, Pain Management, as well as formulations for Veterinary use.
The acquisition of Bryce will allow the Company to expand nationally in the compounding space and further diversify the revenue stream. Based upon Bryce's current operations, the acquisition will add approximately $1.5M in revenue and is expected to improve overall margins. Sunpeaks Ventures plans to quickly grow the license base of Bryce, expand the sales force, and expand the product offers through facility improvements and capital investments. The purchase price was $1.1 million.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: 888-264-4597 or firstname.lastname@example.org
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.
More by this Source
Sunpeaks Ventures Announces Name Change to Pharmagen, Inc.
Jan 14, 2013, 09:24 ET
Sunpeaks Ventures Announces Hiring of Chief Financial Officer
Dec 27, 2012, 13:58 ET
Sunpeaks Ventures Closes $7.5MM Committed Equity Facility with TCA Global Credit Master Fund
Dec 17, 2012, 17:20 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.